Fatemeh Heydari

Fatemeh Heydari

Auto-generated profile, based on publicly available information

Fatemeh Heydari

Children and Neonatal Health Research Center Golestan University of Medical Sciences Gorgan Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Nursing Open
Verified
Journal Article
Open access
HKHomeira Khoddam
Homeira Khoddam
MMMahnaz Modanloo
Mahnaz Modanloo
NMNeda Mehrdad
Neda Mehrdad
FHFatemeh Heydari
Fatemeh Heydari
RTRazieh Talebi
Razieh Talebi
Aim: To explore the experiences of neonatal and NICU nurses on participating in evidence‐based changes in their neonatal pain management practice.Design: It is a qualitative conventional content analysis.Methods: A purposive sample with nurses working in neonatal and NICUs was used. The data were collected through 11 semi‐structured in‐depth individual interviews, five focused group discussions, and observations and analyzed using the conventional content analysis method based on the Elo and Kyngäs model. The COREQ checklist was used for writing the report.Results: Analysis of gathered data led to the emergence of four themes, including ‘being in a supportive and encouraging atmosphere’, ‘a journey from resistance to adherence’, ‘achieving multi‐dimensional improvements’, and ‘facing obstructive challenges’.

14 February 2023 in Journal of Nursing and Midwifery Sciences
Verified
Journal Article
Open access
PDF file
ARAhmad Ramezani
Ahmad Ramezani
SAShahram Ala
Shahram Ala
SESaeed Ehteshami
Saeed Ehteshami
FHFatemeh Heydari
Fatemeh Heydari
ESEbrahim Salehifar
Ebrahim Salehifar
MMMahmood Moosazadeh
Mahmood Moosazadeh
Background: Traumatic brain injury (TBI) causes disability and death in many patients. Objectives: We investigated the effect of memantine on the Glasgow Coma Scale (GCS), serum levels of neuron-specific enolase (NSE), and its effect on sequential organ failure assessment (SOFA) score in TBI patients with GCS 6-12 on days 1, 3, and 7. Methods: Fifty-nine patients were randomly divided into intervention (n = 29) and control (n = 30) groups who received 30mg drug/placebo every 12 hours for seven days with standard treatment, respectively. The acute physiology and chronic health evaluation II and head CT scan findings were collected on the first day, and the Glasgow Outcome Scale Extended 90 was collected three months later. Results: Considering patients with GCS 6 - 12, the SOFA and NSE decreased from day 1 - 7 in both memantine and control groups, about NSE by 21% and 12.6%, respectively. In GCS6-8 subgroup, the NSE decreased by 19.1% in the memantine group and increased by 8.45%, in the control group. In GCS 9 - 12 subgroup, the NSE decreased by 52.6% and 24.43% in the memantine and control groups, respectively. The SOFA changes were significant between memantine and control groups on day 3 in GCS 9 - 12 subgroup (P = 0.01). In the memantine group with GCS 6 - 12, the increase of GCS from day 1 - 7 was significant (29.6%, P = 0.002), and also in both GCS subgroups. Comparing memantine and control groups, the improvement of GCS was significant on days 3 and 7 in GCS 9 - 12 subgroup. Conclusions: This trial showed that memantine improved the neurohormonal and clinical status of TBI patients with GCS 6 - 12.